COVID-19 vaccine type-dependent differences in immunogenicity and inflammatory response: BNT162b2 and ChAdOx1 nCoV-19
Rattachement africain : kr. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Evaluation of the safety and immunogenicity of new vaccine platforms is needed to increase public acceptance of coronavirus disease 2019 (COVID-19) vaccines. Here, we evaluated the association between reactogenicity and immunogenicity in healthy adults following vaccination by analyzing blood samples before and after sequential two-dose vaccinations of BNT162b2 and ChAdOx1 nCoV-19. Outcomes included anti-S IgG antibody and neutralizing antibody responses, adverse events, and proinflammatory cytokine responses. A total of 59 and 57 participants vaccinated with BNT162b2 and ChAdOx1 nCoV-19, respectively, were enrolled. Systemic adverse events were more common after the first ChAdOx1 nCoV-19 dose than after the second. An opposite trend was observed in BNT162b2 recipients. Although the first ChAdOx1 nCoV-19 dose significantly elevated the median proinflammatory cytokine levels, the second dose did not, and neither did either dose of BNT162b2. Grades of systemic adverse events in ChAdOx1 nCoV-19 recipients were significantly associated with IL-6 and IL-1β levels. Anti-S IgG and neutralizing antibody titers resulting from the second BNT162b2 dose were significantly associated with fever. In conclusion, systemic adverse events resulting from the first ChAdOx1 nCoV-19 dose may be associated with proinflammatory cytokine responses rather than humoral immune responses. Febrile reactions after second BNT162b2 dose were positively correlated with vaccine-induced immune responses rather than with inflammatory responses.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- COVID-19 vaccine type-dependent differences in immunogenicity and inflammatory response: BNT162b2 and ChAdOx1 nCoV-19
- Date Crossref
- 02/09/2022
- Éditeur
- Frontiers Media SA
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Ajou University Department of Infectious Diseases pays non établi dans la noticeUniversité ou école supérieure
-
Hallym University Kangnam Sacred Heart Hospital pays non établi dans la noticeÉtablissement de santé
-
Korea University Department of Internal Medicine pays non établi dans la noticeUniversité ou école supérieure
-
International Vaccine Institute pays non établi dans la noticeOrganisation à but non lucratif
-
Hallym University College of Medicine Department of Internal Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Vaccine Innovation Center-KU Medicine (VIC-K) pays non établi dans la noticeInstitution
-
Division of Vaccine Clinical Research pays non établi dans la noticeÉtablissement de santé
Department of Infectious Diseases — Ajou University, Hallym University Kangnam Sacred Heart Hospital et Department of Internal Medicine — Korea University, avec 4 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.